Executive leadership at Vor Biopharma.
Board of directors at Vor Biopharma.
Research analysts covering Vor Biopharma.
Recent press releases and 8-K filings for VOR.
Vor Biopharma Details Progress on Telitacicept for Autoimmune Diseases
VOR
New Projects/Investments
Guidance Update
- Vor Biopharma's core asset, telitacicept, a BAFF/APRIL inhibitor, is being developed for autoimmune diseases, with global Phase III trials underway for myasthenia gravis (MG) and Sjögren's disease.
- The company projects both MG and Sjögren's to be multi-billion dollar opportunities, with the U.S. MG market alone forecasted to exceed $10 billion by the end of the decade.
- Top-line results for the global Phase III MG trial are anticipated in H1 2027, and the first patient for the global Phase III Sjögren's study is expected to be dosed by the end of H1 2026.
- Vor Biopharma maintains a strong financial position with $450 million in cash, providing a runway until mid-2028 to fund its global Phase III trials.
4 days ago
Vor Biopharma Provides Update on Telitacicept Clinical Development and Financial Position
VOR
New Projects/Investments
Guidance Update
- Vor Biopharma possesses a healthy balance sheet with $450 million, providing a runway until mid-2028.
- The company's lead asset, Telitacicept, a BAFF/APRIL inhibitor, is focused on two significant opportunities: myasthenia gravis (MG) and Sjögren's disease, both projected as multi-billion dollar markets.
- Top-line results for the global phase 3 trial in MG are anticipated in H1 2027.
- The global phase 3 trial for Sjögren's disease is expected to dose its first patient by the end of the first half of 2026.
4 days ago
Vor Biopharma provides updates on Telitacicept development and financial outlook
VOR
New Projects/Investments
Guidance Update
Product Launch
- Vor Biopharma is developing Telitacicept, a BAFF/APRIL inhibitor, for Myasthenia Gravis (gMG) and Sjögren's disease.
- The company maintains a healthy balance sheet with $450 million, providing a cash runway until mid-2028.
- Key upcoming catalysts include top-line results for the global Phase 3 gMG trial by H1 2027 and the first patient dosed in the global Phase 3 Sjögren's study by the end of H1 2026.
- Telitacicept targets significant market opportunities, with the U.S. gMG market forecasted to exceed $10 billion by the end of the decade, and Sjögren's disease also presenting multi-billion dollar potential.
4 days ago
Vor Pivots to Autoimmune Focus, Highlights Telitacicept Progress and Strong Financial Position
VOR
New Projects/Investments
Guidance Update
Product Launch
- Vor pivoted in mid-2025 to become an autoimmune company, in-licensing telitacicept, a BAFF/APRIL inhibitor.
- Telitacicept has demonstrated clinical validation in over 8 autoimmune diseases in China, including 3 commercial approvals (systemic lupus, RA, and myasthenia gravis) and 2 BLA submissions (Sjögren's and IgA nephritis).
- The company is currently conducting a global Phase 3 trial for Myasthenia Gravis (MG) and plans to initiate a Sjögren's disease trial in the coming months.
- Vor is well-capitalized with $450 million on its balance sheet, providing a cash runway into mid-2028, which covers the completion of the MG Phase 3 trial and its commercial launch, as well as most of the Sjögren's trial.
- Both MG and Sjögren's are considered multi-billion dollar blockbuster opportunities.
Jan 13, 2026, 6:30 PM
Vor Provides Update on Autoimmune Pipeline and Financial Position at J.P. Morgan Healthcare Conference
VOR
New Projects/Investments
Product Launch
Guidance Update
- Vor has pivoted to an autoimmune powerhouse, in-licensing telitacicept, a BAFF APRIL inhibitor, from RemeGen.
- Telitacicept has been clinically validated in eight plus autoimmune diseases with over 10,000 patients treated in China, demonstrating a favorable safety profile and consistent efficacy.
- The company is conducting a global Phase 3 trial for Myasthenia Gravis (MG) and will soon start a trial for Sjögren's disease, both identified as multi-billion dollar opportunities.
- Vor is well-capitalized with $450 million on its balance sheet, providing a cash runway into mid-2028, covering key milestones including the completion and commercial launch of the MG Phase 3 trial and most of the Sjögren's trial.
Jan 13, 2026, 6:30 PM
Vor Discusses Autoimmune Pipeline Progress and Financial Position
VOR
New Projects/Investments
Guidance Update
Product Launch
- Vor has pivoted to an autoimmune powerhouse (Vor 2.0) and in-licensed telitacicept, a BAFF APRIL inhibitor, which has demonstrated clinical validation in over 8 autoimmune diseases in China, including three commercial approvals.
- The company is currently enrolling patients in its global Phase 3 trial for telitacicept in myasthenia gravis (MG) and plans to initiate a Sjögren's disease trial within the next few months.
- Vor is well-capitalized with $450 million on its balance sheet, providing a cash runway through mid-2028. This funding is anticipated to cover the completion of the MG Phase 3 trial, its commercial launch, and most of the Sjögren's trial.
Jan 13, 2026, 6:30 PM
Vor Biopharma Inc. Reports Preliminary Year-End 2025 Cash and Upcoming Clinical Milestones
VOR
Earnings
New Projects/Investments
Guidance Update
- Vor Biopharma Inc. reported preliminary cash, cash equivalents, and short-term investments of approximately $450 million as of December 31, 2025, which is expected to provide a runway into mid-2028 and fund all key catalysts.
- The company anticipates global Phase 3 topline data for its Myasthenia Gravis program in 1H27.
- A global Phase 3 trial for Sjögren's Disease is scheduled to initiate in 1H26.
- Vor Biopharma will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026.
Jan 12, 2026, 2:55 PM
Vor Biopharma Appoints New Board Members Following $150M PIPE Financing
VOR
Board Change
New Projects/Investments
- Vor Biopharma Inc. has appointed Andrew Levin, M.D., Ph.D., Partner at RA Capital Management, and Wouter Joustra, General Partner at Forbion, to its Board of Directors.
- These appointments follow the company's recently announced $150M PIPE financing, which included participation from both investors.
- Dr. Levin and Mr. Joustra bring expertise in life sciences investment, financing strategy, and board-level oversight, which will be valuable as the company advances its global Phase 3 programs for telitacicept.
- Dr. Levin fills the board seat previously held by Sarah Reed, General Counsel at RA Capital, who resigned.
Dec 23, 2025, 9:01 PM
Vor Biopharma Announces $150 Million Private Placement and Board Appointments
VOR
New Projects/Investments
Board Change
- Vor Biopharma Inc. announced a $150 million private placement through the sale of 13,876,032 shares of its common stock at a price of $10.81 per share.
- The company plans to use the net proceeds to advance the clinical development of telitacicept, including ongoing and new global Phase 3 clinical trials for myasthenia gravis and primary Sjögren's disease, and for general corporate purposes.
- The financing includes participation from institutional investors such as RA Capital Management, Forbion, Frazier Life Sciences, Caligan Partners, Logos Capital, and Venrock Healthcare Capital Partners.
- As part of the private placement, Forbion will be granted the right to appoint one director to Vor Bio’s board of directors.
- Additionally, on December 18, 2025, Andrew Levin and Wouter Joustra were appointed to the Board of Directors, with Andrew Levin designated by RA Capital following the resignation of Sarah Reed.
Dec 18, 2025, 9:00 PM
Vor Bio Announces $150 Million Private Placement
VOR
New Projects/Investments
Board Change
- Vor Bio has entered into a securities purchase agreement for a private placement to sell 13,876,032 shares of its common stock at a price of $10.81 per share.
- The company anticipates gross proceeds of approximately $150 million from this private placement, which is expected to close on or about December 18, 2025.
- The financing includes participation from new and existing institutional investors, with Forbion being granted the right to appoint one director to Vor Bio’s board of directors.
- Vor Bio intends to use the net proceeds to advance the clinical development of telitacicept, including ongoing and new global Phase 3 clinical trials for myasthenia gravis and primary Sjögren's disease, as well as for working capital and general corporate purposes.
Dec 15, 2025, 1:00 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more